Latest Sensei robotic catheter system Stories
ROCKVILLE, Md., July 6 /PRNewswire-USNewswire/ -- A procedure that sends targeted energy into the heart through a catheter can be used to treat a common type of irregular heartbeat, but little is known about the treatment's long-term benefits and the best methods and circumstances for applying it, according to a new report funded by HHS' Agency for Healthcare Research and Quality. The report examines the use of a procedure called radiofrequency catheter ablation to treat a type of...
The Mayo Clinic in Rochester, Minnesota said it has received $48 million in funding from both the federal government and private industry leaders to expand a study looking into a catheter-based treatment for atrial fibrillation, the most common heart arrhythmia in patients over the age of 65.The experimental study, which is being called CABANA, will include 3,000 subjects across 140 health centers around the world and is aimed at determining whether the condition can be dealt with more...
Treating a common heart rhythm disorder by burning heart tissue with a catheter works dramatically better than drug treatments, a major international study has found.One year after undergoing a treatment called catheter ablation, 63 percent of patients with an irregular heartbeat called atrial fibrillation were free of any recurrent atrial arrhythmias or symptoms. By comparison, only 17 percent of those treated with drugs were arrhythmia-free. Results were so convincing the trial was halted...
U.S. scientists say they've found catheter ablation is much more efficient than drugs in treating atrial fibrillation -- a type of abnormal heart rhythm. Research leader Dr. David Wilber, director of Loyola University's Cardiovascular Institute, said he and his colleagues studied catheter ablation -- using a catheter to heat the heart -- in 167 patients at 19 U.S. medical centers. Wilber said one year after undergoing catheter ablation, 63 percent of the patients with atrial fibrillation...
AUSTIN, Texas, May 11 /PRNewswire/ -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has treated more than 2,300 patients with heart rhythm disorders since it launched on May 1, 2008 -- about a fourth of them from outside Central Texas. "In just one year, the physician team at the Texas Cardiac Arrhythmia Institute at St. David's Medical Center, coupled with our unmatched level of technology, has drawn thousands of patients for the advanced treatment of heart...
New Technology Used to Treat Abnormal Heart Rhythms AUSTIN, Texas, March 3 /PRNewswire/ -- On Tuesday, March 3, 2009, the Texas Cardiac Arrhythmia Institute at St. David's Medical Center became the first in the United States to utilize the long-awaited NaviStar(R) RMT ThermoCool(R) Catheter to treat abnormal heart rhythms, or arrhythmias, since the new technology received FDA approval on Friday, Feb. 27, 2009. The NaviStar(R) RMT ThermoCool(R) Catheter for radiofrequency (RF) ablation is...
Cardima, Inc. (OTCBB: CADM), a medical device company focused on the treatment of Atrial Fibrillation ("AF") and manufacturer of the Cardima Surgical Ablation System, the EP Ablation System, and the PATHFINDER(R) family of diagnostic microcatheters, is pleased to announce the establishment of its Surgical Ablation Training Program and Center of Excellence at Stamford Hospital, Stamford, Connecticut, for the Cardima Surgical Ablation System. Stamford Hospital is an internationally recognized...
St. Jude Medical, Inc. (NYSE:STJ) today announced it has received approval for European CE Marking of its SJM Confirm(TM) implantable cardiac monitor (ICM), a compact device designed to detect atrial fibrillation (AF) and other abnormal heart rhythms. About the size of a computer thumb drive, the SJM Confirm ICM is the smallest implantable cardiac monitor available. It is implanted just under the skin (subcutaneously) in the upper chest region and can be implanted in an outpatient...
Endosense, a medical technology company focused on enabling the broad adoption of catheter ablation for the treatment of cardiac rhythm disorders, has launched the TOCCATA (TOuCh+ for CATheter Ablation) clinical study to evaluate the safety of the TactiCath(TM) system with enrollment gaining momentum. TOCCATA is a 70 patient European multi-center safety study. Constructed to gain the CE mark for the treatment of atrial arrhythmias, secondary endpoints were designed to evaluate the value of...
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, today announced the release of its new atrial fibrillation (AF) reporting package to enhance its current AF Management Program. The CardioNet AF Management Program offers a robust and comprehensive tool to the physician for the diagnosis, treatment and management of their AF patients. The program additionally provides physicians with an...
